Adult Nephrology Residency Training Program

Faculty Research Grants

Dr. Richard Austin

1. 2013-2018 Role of TDAG51 in apoptotic cell death associated with cardiovascular disease (GIA)
  Funding Source: CIHR
  Funding: $813,920
  Duration: 01/04/13-30/03/18
2. 2011 – 2014 TDAG51 in vascular calcification associated with chronic renal disease (GIA)
  Funding Source: CIHR
  Funding: $351,765
  Duration: 01/01/11-31/03/14
3. 2013-2016 Contribution of cell surface GRP78 to the development and progression of atherothrombosis (GIA)
  Funding Source: HSFC
  Funding: $307,962
  Duration: 01/07/13-31/06/16
4. 2008-2013 Identification and Characterization of Novel Targets and Therapeutic Strategies that Decrease Atherothrombotic Disease (Program Grant)
  Funding Source: HSFC
  Funding: $1,250,000
  Duration: 01/07/08-31/06/13
5. 2012-2017 Role of endoplasmic reticulum stress in atherothrombotic disease (Salary Support)
  Funding Source: HSFO
  Funding: $425,000
  Duration: 01/07/12-30/06/17

Dr. Scott Brimble

1. 2013-Present Trial of hemodialysis based exercise for strength improvement Study
  Principal Investigator: Scott Brimble
  Funding Source: Division of Nephrology Research
  Funding: $45,000.00, Principal Investigator 
2. 2012-Present Impact of cholecalciferol supplementation on LV mass in peritoneal dialysis patients: a randomized controlled trial
  Principal Investigator: Scott Brimble
  Funding Source: Kidney Foundation of Canada
  Duration: $60,000
3. 2011-Present Web-based IHCA for Successful Home Dialysis
  Funding Source: Scott Brimble
  Funding: HAHSO AFPO grant
  Duration: $150,000

Dr. Catherine Clase

1. 2012-2013 Bio-CANPREDDICT.  Bioimpedance as a predictor of cardiovascular outcomes in patients with chronic kidney disease. (A substudy of Can-PREDDICT).
  Nominated principal investigator: Catherine Clase
  Co-principal investigator: Azim Gangji
  Funding Source: Kidney Foundation of Canada
  Funding: $100,000
  Duration: over 2 years July 2012 to Sept 2013
2. 2012-2014 R-IMPACT.  Remote Ischemic Preconditioning to Prevent Acute Kidney Injury after Cardiac Surgery. (Pilot)
  Co-investigator: Catherine Clase
  Principal investigators: Walsh M, Devereaux PJ; Co-investigators Garg AX, Teoh K, Guyatt G, Lamy A, Eikelboom J, Whitlock R
  Funding Source: Cannectin
  Funding: $124,000
  Duration: Sept 2012 to Sept 2014
3. 2013-2019 TESTING.  Steroids to reduce renal outcomes in IgA nephropathy
  Co-investigator: Catherine Clase
  Principal investigators: Michelle Hladunewich, Sean Barbour;
  Co-investigators: Brenda Hemmelgarn, Adeera Levin, Dan Cattran, Heather Reich, Neesh Pannu, William Clark, Claudio Rigatto, Manish Sood, Steven Soroka
  Funding Source: CIHR
  Funding: $884 666
  Duration: Sept 2013 to Sept 2019
4. 2013-2015 ROSIE.  A pilot study to evaluate the feasibility and safety of performing a double blind, placebo-controlled, randomized controlled trial of The Routine use of SSRI’s at the Initiation of End-stage Renal Disease Treatment.
  Co-investigator: Catherine Clase
  Principal investigator: Vanita Jassal;
  Co-investigators: Ron Wald, Marisa Batistella, Roger McIntyre, Kevin Thorpe, Muhammad Mumdani
  Funding Source: CIHR
  Funding: $229 170
  Duration: Sept 2013 to Sept 2015

Dr. Jeffrey G. Dickhout

1. 2014-2017 Inhibition of endoplasmic reticulum (ER) stress in the prevention of kidney disease
  Principal Applicant: Jeffrey Dickhout
  Funding Source: Kidney Foundation of Canada (KFC) Krescent New Investigator Award
  Funding: 195,000 (Canadian dollar)
  Funding Competitive? Yes
  Duration: July 2014 to June 2017
2. 2014-2017 Role of the unfolded protein response in hypertension-induced end organ damage
  Principal Applicant: Jeffrey Dickhout
  Co-investigator: Kjetil Ask
  Collaborator: Joan Krepinsky
Jeffrey Dickhout
  Funding Source: Canadian Institutes of Health Research (CIHR) open operating grant program
  Funding: 323,142 (Canadian dollar)
  Funding Competitive? Yes
  Duration: March 2014 to March 2017
3. 2013-2016 Endoplasmic reticulum (ER) stress in the progression of proteinuric kidney disease
  Principal Investigator: Jeffrey Dickhout
  Funding Source: McMaster University - Department of Medicine Internal Career Research Award
  Funding: 90,000 (Canadian dollar)
  Funding Competitive? Yes
  Duration: July 2013 July 2016
4. 2014-2015 Inhibition of Acute Kidney Injury through CHOP/GADD153 suppression
  Principal Applicant: Jeffrey Dickhout
  Funding Source: Kidney Foundation of Canada (KFC) Krescent
  Funding: 50,000 (Canadian dollar)
  Funding Competitive? Yes
  Duration: July 2014 to July 2015
5. 2011-2014 Role of endoplasmic reticulum (ER) stress in the development of kidney disease
  Principal Investigator: Jeffrey Dickhout
  Funding Source: Canadian Institutes of Health Research (CIHR)
  Operating Grant-PA: Sodium and Health
  Funding: 227,019 (Canadian dollar)
  Funding Competitive? Yes
  Duration: October 2011to October 2014

Dr. Azim Gangji

1. 2014  
  Funding Source: McLaughlin Foundation Transplantation Grant
  Funding: $70,000 (Co-Investigator)
  Since: January 2014
2. 2013 Biovision Study
  Funding Source: PSI
  Funding: 162,000
  Duration: September 2013 - 2015
3. 2012-2016 Fibrocytes in Glomerulonephritis
  Funding Source: CIHR Operating Grant
  Funding: $400,000 (PI)
  Duration: September 2012-August 2016

Dr. Joan Krepinsky

1. 2011-2014 TDAG51 in vascular calcification associated with chronic renal disease
  Co-investigators: Joan Krepinsky and Dr. R. Austin
  Funding Source: Canadian Institutes of Health Research (CIHR)
  Funding: $117,255 per year for 3 years
2. 2011-2014 SREBP in the pathogenesis of diabetic nephropathy
  Primary Investigator: Joan Krepinsky
  Funding Source: Canadian Diabetes Association
  Funding: $75,000 1st year; $100,000 2nd and 3rd years
3. 2012-2017 The role of ADAM17 in the pathogenesis of diabetic nephropathy
  Principal Investigator: Joan Krepinsky
  Funding Source: Canadian Institutes of Health Research (CIHR)
  Funding: $113,846 per year for 5 years
4. 2014-2019 Does follistatin protect against diabetic nephropathy?
  Principal Investigator: Joan Krepinsky
  Funding Source: Canadian Institutes of Health Research (CIHR)
  Funding: $105,324 per year for 5 years
5. 2014-2019 TDAG51 in vascular calcification associated with chronic renal disease
  Co-Investigators: Joan Krepinsky and Dr. R. Austin
  Funding Source: Amgen Research – Nephrology
  Funding: $2,000,000 over 5 years

Dr. Peter Margetts

1. 2014  
  Funding Source: McLaughlin Foundation Transplantation Grant
  Funding: $70,000 (PI)
  Since: January 2014
2. 2013-2015  
  Funding Source: Kidney Foundation of Canada, Biomedical Operating Grant
  Funding: $100,000 (PI)
  Duration: July 2013 – June 2015
3. 2012-2016 Fibrocytes in Glomerulonephritis
  Funding Source: CIHR Operating Grant
  Funding: $400,000
  Duration: September 2012-August 2016

Dr. Darin Treleaven

1. 2010-2014 Canadian Living Kidney Donor Safety Study
  Primary Investigator: A. Garg
  Co-investigator: Darin Treleaven
  Funding Source: Canadian Institutes of Health Research Operating Grant
  Funding: 100,000 per year
  Duration: 2010-2014
2. 2010-2015 Outcomes After Failed Kidney Transplant
  Primary Investigator: J. Gill/G.Knoll
  Co-investigator: Darin Treleaven
  Funding Source: Canadian Institutes of Health Research Operating Grant
  Funding: 864,000 for 5 yrs
  Duration: 2010-2015
3. 2006-2014 Canadian Conversion Study To Study Atherosclerosis in Renal Transplant Recipients
  Primary Investigator: A. House
  Co-investigator: Darin Treleaven
  Funding Source: Wyeth Canada Investigator Initiated Research Operating Grant
  Funding: 900,000 for 5 years
  Duration: 2006-2014

Dr. Michael Walsh

1. 2014-2015 Trial of intense versus liberalized serum phosphate control in dialysis patients (TARGET)
  Primary Investigator: Michael Walsh, Ron Wald
  Co-investigators: A Garg, B Manns, P Parfrey
  Funding Source: Canadian Institutes of Health Research
  Funding: $168,394
  Duration: 2014 – 2015
2. 2014 – 2015 Protection of the Heart with Aldosterone antagonism in End-stage renal disease (PHASE 2) Trial
  Primary Investigator: Michael Walsh, PJ Devereaux, Ron Wald
  Co-investigators: B. Barrett, G Bueti, S DeSerres, A Garg, C Hawley, R Holden, A Levin, F Madore, B Manns, D Mendelssohn, S Nessim, P Parfrey, V Perkovic, J Pogue, A Smyth, M Sood, R Suri, K Tennankore, M Tonelli, F Xie
  Funding Source: Canadian Institutes of Health Research
  Funding: $100,000
  Duration: 2014 – 2015
3. 2014 – 2016 Hemodialysis Outcomes and Symptoms Assessment: Troponin I Measurement
  Primary Investigator: Michael Walsh
  Co-investigator: Peter Kavsak
  Funding Source: Hamilton Academic Health Sciences Organization Innovation Fund
  Funding: $200,000
  Duration: 2014 – 2016
4. 2013 – 2014 Hemodialysis Outcomes and Symptoms Assessment: measurement of recovery time
  Primary Investigator: Michael Walsh
  Co-investigators: Scott Brimble, PJ Devereaux, Gordon Guyatt, Peter Kavsak
  Funding Source: Division of Nephrology/Gambro
  Funding: $36,000
  Duration: 2013 – 2014
5. 2013 – 2017 Integration of clinical, biomarker, and genetic data for prediction of adverse outcomes in diabetes
  Primary Investigator: Guillaume Pare
  Co-investigators: Sonia Anad, Joseph Beyene, Michael Grignon, Johannes Mann, Matt McQueen, David Meyre, Michael Walsh and Salim Yusuf
  Funding Source: CIHR
  Funding: $999,071
  Duration: 2013 – 2017
6. 2013 – 2014 Intensive vs liberalized phosphate control in hemodialysis recipients
  Primary Investigators: Michael Walsh and Ron Wald
  Co-investigators: Amit Garg, Braden Manns, Patrick Parfrey
  Funding Source: CIHR
  Funding: $100,000
  Duration: 2013 – 2014
7. 2013 – 2014 Pilot trial of Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE)
  Primary Investigators: Michael Walsh and Ron Wald
  Co-investigators: PJ Devereaux, Amit Garg, Joe Bueti, Braden Manns
  Funding Source: CIHR
  Funding: $86,439
  Duration: 2013 – 2014
8. 2012 – 2013 Pilot trial of Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE)
  Primary Investigator: Michael Walsh
  Co-investigators: Ron Wald, Braden Manns, Amit Garg, Joe Bueti
  Funding Source: Canadian Network and Centre for Trials internationally
  Funding: $39,125
  Duration: 2012 – 2013
9. 2012 – 2013 Pilot trial of Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE)
  Primary Investigator: Michael Walsh
  Funding Source: Pfizer International Investigator Initiated Research
  Funding: $120,000
  Duration: 2012 – 2013
10. 2012 – 2013 Pilot trial of Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE)
  Primary Investigator: Michael Walsh
  Funding Source: McMaster Division of Nephrology/Gambro
  Funding: $80,000
  Duration: 2012 – 2013
11. 2012 – 2013 Intensive vs liberalized phosphate control in hemodialysis recipients
  Primary Investigators: Ron Wald and Michael Walsh
  Funding Source: McMaster Division of Nephrology/Gambro Funding
  Funding: $67,650
  Duration: 2012 – 2013
12. 2012 – 2016 Fibrocytes in glomerulonephritis
  Primary Investigators: Peter Margetts, Martin Kolb, Michael Walsh
  Funding Source: CIHR
  Funding: $321,489
  Duration: 2012 – 2016
13. 2011 – 2014 Curcumin to prevent perioperative complications after elective abdominal aortic aneurysm repair
  Primary Investigator: Amit Garg
  Co-investigators: DEVEREAUX, Philip J; HARRIS, Jeremy; HILL, Andrew B; HIREMATH, Swapnil; HLADUNEWICH, Michelle A; IYER, Vikram; JAMES, Matthew T; LINDSAY, Thomas F; MAGGISANO, Robert; MOIST, Louise M; PANNU, Neesh I; PAPIA, Giuseppe; RICHARDSON, Robert M; SHARAN, Sumit; THIESSEN PHILBROOK, Heather; TOBE, Sheldon W; WALD, Ron; WALSH, Michael W
  Funding Source: CIHR
  Funding: $322,419
  Duration: 2011 – 2014
14. 2011 – 2014 The CAnadian KidNey KNowledge Translation and Generation NETwork (CANN-NET)
  Primary Investigators: MANNS, Braden J; LEVIN, Adeera; GARG, Amit; HEMMELGARN, Brenda R; KLARENBACH, Scott; PARFREY, Patrick S; SAMUEL, Susan M
  Co-investigators: EVANS, Michael F; MACCALLUM, Lori A; MADORE, François; TONELLI, Marcello; WALD, Ron; WALSH, Michael W; ZAPPITELLI, Michele
  Funding Source: CIHR
  Funding: $600,000
  Duration: 2011 – 2014
15. 2012 – 2016 Preventing Peri-operative Acute Kidney Injury: SIRS POISE-2 Sub-studies
  Primary Investigator: Amit Garg
  Co-investigators: ALONSO, Pablo ; AVEZUM, Alvaro ; BICCARD, Bruce McClure ; BOTTO, Fernando ; CHAN, Matthew Tak Vai ; CUERDEN, Meaghan S ; DEVEREAUX, Philip James ; KURZ, Andrea ; LAMONTAGNE, Francois ; LAMY, André ; LE MANACH, Yannick ; MALAGA, German ; PAPARELLA, Domenico ; PARIKH, Chirag R ; POGUE, Janice Margaret ; QUANTZ, Mackenzie Alexander ; SESSLER, Daniel I. ; SHAH, MITESH KIRTIBHAI ; SHAH, Pallav ; WALSH, Michael William ; WHITLOCK, Richard ; XAVIER, Denis Bharathi ; ZUO, Yunxia
  Funding Source: CIHR
  Funding: $502,500
  Duration: 2012 – 2016
16. 2012 – 2016 Perioperative Ischemia Evaluation 2 (POISE-2)
  Primary Investigator: PJ Devereaux
  Co-investigators: ALONSO, Pablo ; ANAND, Sonia Savitri ; BAIGENT, Colin ; BALAJI, Packianathaswam ; BEATTIE, William Scott ; BERWANGER, Otavio ; BHANDARI, Mohit ; BICCARD, Bruce McClure ; BOTTO, Fernando ; CHAN, Matthew Tak Vai ; CHOW, Clara Kayei ; CHROLAVICIUS, Susan M ; CONEN, David ; COOK, Deborah Joanne ; DOUKETIS, James D. ; EIKELBOOM, John Wa ; GARG, Amit ; GERSTEIN, Hertzel C ; GHALI, William Amin ; GRAHAM, Michelle Monique ; GUYATT, Gordon Henry ; HART, Robert Glen ; HILL, Michael Douglas ; JACKA, Michael John ; JACOBSOHN, Eric ; KARTHIKEYAN, Ganesan ; KEARON, Clive ; KURZ, Andrea ; LAMY, André ; LANDONI, Giovanni ; LESLIE, Kate ; LURATI BUSE, Giovanna Attilia Luisa ; MALAGA, German ; MCALISTER, Finlay Aleck ; MEYHOFF, Christian Sylvest ; MILLER, Scott Alan ; MRKOBRADA, Marko ; O'DONNELL, Martin James ; PARLOW, Joel L. ; PAUL, James Edward ; POGUE, Janice Margaret ; SCHRICKER, Thomas Peter Stephan ; SESSLER, Daniel I. ; SIMUNOVIC, Marko ; SRINATHAN, Sadeesh Kumar ; TEOH, Kevin Hong To ; TORRES, David ; VILLAR, Juan Carlos ; WALSH, Michael William ; WANG, Chew Yin ; WHITLOCK, Richard ; WIJEYSUNDERA, Duminda Nalaka ; XAVIER, Denis Bharathi ; YANG, Homer ; YUSUF, Salim
  Funding Source: CIHR
  Funding: $3,684,006
  Duration: 2012 – 2016
17. 2011 – 2013 Perioperative Medications and Acute Kidney Injury: a VISION substudy
  Primary Investigators: Amit Garg, PJ Devereaux, Michael Walsh
  Co-investigators: Amber Molnar, Marko Mrkobrada, Mitesh Shah
  Funding Source: CIHR
  Funding: $119,920
  Duration: 2011 – 2013
18. 2011 – 2013 Markers of cardiac injury after cardiac surgery
  Primary Investigator: Richard Whitlock
  Co-investigators: Michael Walsh, PJ Devereaux, Salim Yusuf, Chirag Parihk, Amit Garg, John Eikelboom
  Funding Source: Hamilton Health Sciences New Investigator
  Funding: $25,000
  Duration: 2011 – 2013
19. 2010 – 2015 Steroids in Cardiac Surgery Trial (SIRS)
  Primary Investigators: Kevin Teoh and Richard Whitlock
  Co-investigators: AKAR, Ruchan A ; BAGSHAW, Sean M ; BHATT, Deepak L. ; CARRIER, Michel ; DEVEREAUX, Philip James ; FINEGAN, Barry A. ; FREMES, Stephen Edward ; GARG, Amit ; HEALEY, Jeff Sean ; KARTHIKEYAN, Ganesan ; KIESER, Teresa Mary ; LAMY, André ; LEGARE, Jean-François ; MAGGIONI, Aldo Pietro ; MARTIN, Billie-Jean ; MENG, Xu ; NOVICK, Richard J. ; POGUE, Janice Margaret ; QUANTZ, Mackenzie Alexander ; ROSS, David Burns ; SINGAL, Rohit Kuman ; THABANE, Lehana ; WALSH, Michael William
  Funding Source: CIHR
  Funding: $4,062,400
  Duration: 2010 – 2015
20. 2009 – 2011 Remote ischemic preconditioning in cardiac surgery trial
  Proposal Author: Michael Walsh
  Primary Investigator: Michael Walsh
  Co-investigators: PJ Devereaux, Amit Garg
  Funding Source: CIHR – RCT Mentoring Program
  Funding: $20,000
  Duration: 2009 – 2011
21. 2010 – 2015 Preventing chronic kidney disease by avoiding peri-operative acute, transient elevations in serum creatinine
  Primary Investigators: Amit Garg and Andre Lamy
  Co-investigators: Michael Walsh, Salim Yusuf, Chirag Parikh, PJ Devereaux, Steve Coca, R. Novak, Richard Cook
  Funding Source: CIHR
  Funding: $196,550
  Duration: 2010 – 2015
22. 2010 – 2017 Plasma exchange and glucocorticoids in ANCA associated vasculitis trial (PEXIVAS Canada)
  Proposal Author: Michael Walsh
  Primary Investigator: Bill Clark
  Co-investigators: Michael Walsh, Amit Garg, Catherine Clase, Azim Gangji, Nader Khalidi, Simon Carette, Heather Reich, Ron Wald, Katerina Pavenski, David Barth, Braden Manns, Dan Muruve, Neesh Pannu
  Funding Source: CIHR
  Funding: $403,518
  Duration: 2010 – 2017
(NOTE: I was not eligible to act as the PI because the PI must hold a faculty appointment. I am, however, leading the conduct and implementation of this study.)
23. 2009 – 2014 Plasma exchange and glucocorticoids in ANCA associated vasculitis trial (PEXIVAS Australia)
  Proposal Author: Michael Walsh
  Primary Investigator: Chen Au Peh
  Co-investigators: Michael Walsh, Carmel Hawley, Vlado Perkovic, David Jayne, Peter Merkel, Giles Walter, Jonathon Craig, Steven Kerr
  Funding Source: National Health Medical Research Council (Australia)
  Funding: $615,855 (Aus)
  Duration: 2009 – 2014